MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors |
Cymbaluk-Ploska, Aneta
(Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University)
Chudecka-Glaz, Anita (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) Surowiec, Anna (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) Pius-Sadowska, Ewa (General Pathology Department, Pomeranian Medical University) Machalinski, Boguslaw (General Pathology Department, Pomeranian Medical University) Menkiszak, Janusz (Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University) |
1 | Balduyck M, Zerimech F, Gouyer V, et al (2000). Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. Clin Exp Metastasis, 18, 171-8. DOI |
2 | Bandiera E, Romani C, Specchia C, et al (2011). Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev, 20, 2496-506. DOI |
3 | Baruch RR, Melinscak H, Lo J, et al (2001). Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int, 25, 411-20. DOI |
4 | Bodey B, Bodey B, Jr., Siegel SE, et al (2001). Immunocytochemical detection of matrix metalloproteinase expression in prostate cancer. In Vivo, 15, 65-70. |
5 | Chambers AF, Matrisian LM (1997). Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst, 89, 1260-70. DOI |
6 | Chen WT, Gao X, Han XD, et al (2014). HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev, 15, 101-5. DOI |
7 | Choi JW, Ahn SE, Rengaraj D, et al (2011). Matrix metalloproteinase 3 is a stromal marker for chicken ovarian cancer. Oncol Lett, 2, 1047-51. DOI |
8 | Chudecka-Glaz AM (2015). ROMA, an algorithm for ovarian cancer. Clin Chim Acta, 440, 143-51. DOI |
9 | Coticchia CM, Curatolo AS, Zurakowski D, et al (2011). Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol, 123, 295-300. DOI |
10 | Folkman J, Cotran R (1976). Relation of vascular proliferation to tumor growth. Int Rev Exp Pathol, 16, 207-48. |
11 | Fu Z, Xu S, Xu Y, et al (2015). The expression of tumor-derived and stromal-derived matrix metalloproteinase 2 predicted prognosis of ovarian cancer. Int J Gynecol Cancer, 25, 356-62. DOI |
12 | Kristjansdottir B, Levan K, Partheen K, et al (2013). Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer. Gynecol Oncol, 131, 52-8. DOI |
13 | Li F, Tie R, Chang K, et al (2012). Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer, 12, 258. DOI |
14 | Li Y, Jin X, Kang S, et al (2006). Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol Oncol, 101, 92-6. DOI |
15 | Menon R, Fortunato SJ (2004). The role of matrix degrading enzymes and apoptosis in rupture of membranes. J Soc Gynecol Investig, 11, 427-37. DOI |
16 | Molina R, Escudero JM, Auge JM, et al (2011). HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol, 32, 1087-95. DOI |
17 | Muyldermans M, Cornillie FJ, Koninckx PR (1995). CA125 and endometriosis. Hum Reprod Update, 1, 173-87. DOI |
18 | Sheu BC, Lien HC, Ho HN, et al (2003). Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and recurrence of human cervical cancer. Cancer Res, 63, 6537-42. |
19 | Ortiz-Munoz B, Aznar-Oroval E, Garcia Garcia A, et al (2014). HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biol, 35, 7249-58. DOI |
20 | Partheen K, Kristjansdottir B, Sundfeldt K (2011). Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol, 22, 244-52. DOI |
21 | Winarto H, Laihad BJ, Nuranna L (2014). Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pac J Cancer Prev, 15, 1949-53. DOI |
22 | Smolarz B, Szyllo K, Romanowicz-Makowska H, et al (2003). PCR analysis of matrix metalloproteinase 3 (MMP-3) gene promoter polymorphism in ovarian cancer. Pol J Pathol, 54, 233-8. |
23 | Sun N, Zhang Q, Xu C, et al (2014). Molecular regulation of ovarian cancer cell invasion. Tumour Biol, 35, 11359-66. DOI |